Relationship between exposure and toxicity in high-dose chemotherapy with cyclophosphamide, thiotepa and carboplatin

Annals of Oncology

Volumn 13, Issue 3, 2002, Pages 374-384

  Huitema, A D R ^a   Spaander, M ^a   Mathot R A A ^a   Tibben, M M ^b   Holtkamp, M J ^b   Beijnen, J H ^b   Rodenhuis, S ^a  

^a SLOTERVAART HOSPITAL   (Netherlands)

^b ANTONI VAN LEEUWENHOEK HOSPITAL   (Netherlands)

Author keywords

Carboplatin; Cyclophoshamide; High dose chemotherapy; Pharmacokinetics; Thiotepa; Toxicity

Indexed keywords

4 HYDROXYCYCLOPHOSPHAMIDE; AMINOTRANSFERASE; CARBOPLATIN; CYCLOPHOSPHAMIDE; MESNA; PHOSPHORAMIDE MUSTARD; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; TEPA; THIOTEPA; ANTINEOPLASTIC AGENT; CTCB REGIMEN;

AREA UNDER THE CURVE; ARTICLE; BLEEDING; BLOOD SAMPLING; CARDIOTOXICITY; CONTROLLED STUDY; DIARRHEA; DISEASE SEVERITY; DRUG EXPOSURE; DRUG MEGADOSE; FEMALE; HEMORRHAGIC CYSTITIS; HUMAN; INDIVIDUALIZATION; LUNG TOXICITY; MAJOR CLINICAL STUDY; MALE; MALIGNANT NEOPLASTIC DISEASE; METABOLIC DISORDER; MUCOSA INFLAMMATION; NAUSEA AND VOMITING; NEUROPATHY; OTOTOXICITY; PRIORITY JOURNAL; RASH; STEM CELL TRANSPLANTATION; ULTRAFILTRATION; VEIN OCCLUSION; BREAST TUMOR; DOSE RESPONSE; HALF LIFE TIME; METABOLISM; MIDDLE AGED; NEOPLASM; OVARY TUMOR; TISSUE DISTRIBUTION;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; AREA UNDER CURVE; BREAST NEOPLASMS; CARBOPLATIN; CYCLOPHOSPHAMIDE; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HALF-LIFE; HUMAN; MALE; MIDDLE AGE; NEOPLASMS, GERM CELL AND EMBRYONAL; OVARIAN NEOPLASMS; SUPPORT, NON-U.S. GOV'T; THIOTEPA; TISSUE DISTRIBUTION; HUMANS; MIDDLE AGED;

EID: 0036018898     PISSN: 09237534     EISSN: None     Source Type: Journal    
DOI: 10.1093/annonc/mdf052     Document Type: Article

References (36)

1. The clinical pharmacology of alkylating agents in high-dose chemotherapy
2. High-dose chemotherapy regimens for solid tumors
3. Conventional-dose chemotherapy compared with high-dose chemotherapy plus autologous hematopoietic stem-cell transplantation for metastatic breast cancer
4. Tailored fluorouracil, epirubicin, and cyclophosphamide compared with marrow-supported high-dose chemotherapy as adjuvant treatment for high-risk breast cancer: A randomised trial
5. High-dose chemotherapy in breast cancer - Interpretation of randomized trials
6. A phase I/II study of cyclophosphamide, thiotepa, and carboplatin with autologous bone marrow transplantation in solid tumor patients
7. Randomised trial of high-dose chemotherapy and haemopoietic progenitor-cell support in operable breast cancer with extensive axillary lymph-node involvement
8. Feasibility of multiple courses of high-dose cyclophosphamide, thiotepa, and carboplatin for breast cancer or germ cell cancer
9. Feasibility and toxicity study of a high-dose chemotherapy regimen for autotransplantation incorporating carboplatin, cyclophosphamide and thiotepa
10. A multi-center prospective phase II study of high-dose chemotherapy in germ-cell cancer patients relapsing from complete remission
11. Chemistry, pharmacology and pharmacokinetics of N,N′,N-triethylenethiophosphoramide (ThioTEPA)
12. A search for new metabolites of N,N′,N″-triethylenethiophosphoramide
13. Reduction of cyclophosphamide bioactivation by thioTEPA: Critical sequence dependency in high-dose chemotherapy regimens
14. Cyclophosphamide pharmacokinetics: Correlation with cardiac toxicity and tumor response
15. Correlation of high-dose cyclophosphamide, cisplatin, and carmustine pharmacokinetics to response and toxicity in patients with primary breast cancer
16. A phase I/II study of high-dose cyclophosphamide, cisplatin, and thiotepa followed by autologous bone marrow and granulocyte colony-stimulating factor-primed peripheral-blood progenitor cells in patients with advanced malignancies
17. Dosing of thiotepa for myeloablative therapy
18. Pharmacokinetics and pharmacodynamics of carboplatin administered in a high-dose combination regimen with thiotepa, cyclophosphamide and peripheral stem cell support
19. Guidelines for reporting of adverse drug reactions
20. Sampling technique from central venous catheters proves critical for pharmacokinetic studies
21. Simultaneous determination of N,N′,N″-triethylenethiophosphoramide, cyclophosphamide and some of their metabolites in plasma using capillary gas chromatography
22. High performance liquid chromatographic determination of the stabilized cyclophosphamide metabolite 4-hydroxycyclophosphamide in plasma and red blood cells
23. Simple and selective determination of the cyclophosphamide metabolite phosphoramide mustard in human plasma using high-performance liquid chromatography
24. Validated method for the determination of carboplatin in biological fluids by Zeeman atomic absorption spectrometry
25. The importance of modeling interoccasion variability in population pharmacokinetic analyses
26. Population pharmacokinetics of thiotepa and its active metabolite tepa in patients undergoing high-dose chemotherapy
27. Validation of techniques for the prediction of carboplatin exposure: Application of Bayesian methods
28. A mechanism-based pharmacokinetic model for the cytochrome P450 drug-drug interaction between cyclophosphamide and thiotepa and the autoinduction of cyclophosphamide
29. High-dose N,N′,N″-triethylenethiophosphoramide (thiotepa) with autologous bone marrow transplantation: Phase I studies
30. The syndrome of hepatic veno-occlusive disease after marrow transplantation
31. Cellular target of cyclophosphamide toxicity in the murine liver: Role of glutathione and site of metabolic activation
32. Hepatic dysfunction following busulfan and cyclophosphamide myeloablation: A retrospective, multicenter analysis
33. Nonpredictable pharmacokinetic behavior of high-dose cyclophosphamide in combination with cisplatin and 1,3-bis(2-chloroethyl)-1-nitrosourea
34. Bone marrow reconstitution after high-dose chemotherapy and autologous peripheral blood progenitor cell transplantation: Effect of graft size
35. Busulfan disposition: The role of therapeutic monitoring in bone marrow transplantation induction regimens